Gilead's search for the next great liver drug won't end with its FXR agonist

Gilead's search for the next great liver drug won't end with its FXR agonist

Source: 
Biopharma Dive
snippet: 

On Friday, Gilead Sciences highlighted clinical data showing one of its candidates offered benefits across multiple liver diseases. Analysts, however, remain unconvinced the drug can stack up to rival therapies that work in a similar way.